Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation

Medical Science Monitor

Volumn 10, Issue 8, 2004, Pages

  Surowiak, Paweł ^a   Paluchowski, Piotr ^b   Dziȩgiel, Piotr ^a   Wysocka, Teresa ^a   Wojnar, Andrzej ^c   Spaczyński, Marek ^d   Zabel, Maciej ^a,d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Klinikum Pinneberg   (Germany)

^c Lower Silesia Center of Oncology   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

AgNORs; Breast cancer; Immunocytochemistry; Ki67; Metallothioneins

Indexed keywords

KI 67 ANTIGEN; METALLOTHIONEIN; PARAFFIN; SILVER;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME NOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; METALLOTHIONEIN; NEOPLASM STAGING;

EID: 4444244080     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rosen PP: Breast Pathology, Lippincort-Raven Publishers, Philadelphia, New York, 1997
2. Toi M, Bando H, Saji S: Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy. Med Sci Monit, 2003; 9(5): RA110-RA115
3. Fitzgibbons PL, Page DL, Weaver D et al: Prognostic factors in breast cancer. College of American Pathologist consensus statement 1999. Arch Pathol Lab Med, 2000; 124: 966-78
4. Kagi JHR: Overview of metallothionein. Methods Enzymol, 1991; 205: 613-26
5. Kagi JHR, Schafer A: Biochemistry of metallothionein. Biochemistry, 1988; 27: 8509-15
6. Hammer DH: Metallothionein. Annu Rev Biochem, 1986; 55: 913-51
7. Konecki J, Biazejowski J, Slowinski J, Helewski K: Influence of chronic cadmium exposure during pregnancy on DNA synthesis in different organs of rat offspring. Med Sci Monit, 2000; 6(6): 1077-81
8. Ebadi M, Leuschen MP, El Refaey H et al: The antioxidant properties of zinc and metallothionein. Neurochem Int, 1996; 29: 159-66
9. Schwarz MA, Lazo JS, Yalowich JC et al: Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci USA, 1995; 92: 4452-56
10. Schmidt CJ, Hamer DH: Cell specificity and an effect of ras on human metallothionein gene expression. Proc Natl Acad Sci USA, 1986; 83: 3346-50
11. Jin R, Bay BH, Chow VT, Tan PH: Metallothionein IF mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat, 2001; 66 (3): 265-72
12. Hishikawa Y, Koji T, Dhar DK et al: Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer, 1999; 81(4): 712-20
13. Oyama T, Take H, Hikino T et al: Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology, 1996; 53(2): 112-17
14. Meskel HH, Cherian MG, Martinez VJ et al: Metallothionein as a prolferative compartment marker for DNA flow cytometry. Mod Pathol, 1993; 6(6): 755-60
15. Studer R, Vogt CP, Cavigelli M et al: Metallothionein accretion in human hepatic cells is linked to cellular proliferation. Biochem J, 1997; 328: 63-67
16. Dziȩgiel P, Forgacz J, Suder E et al: Prognostic significance of mctallothionein expression in correlation with Ki67 expression in adenocarcionmas of large intestine. Histol Histopatol, 2003; 18(2): 401-7
17. Ioachim E, Kamina S, Demon A et al: Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, p53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res, 1999; 19(3A): 2133-39
18. Ioachim EE, Charchanti AV, Stavropoulos NE et al: Localization of metallothionein in urothelial carcinoma of human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. Anticancer Res, 2001; 21(3B): 1757-61
19. Wrigley E, Verspaget HW, Jayson GC, McGown AT: Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol, 2000; 126: 717-21
20. Andrews PA, Murphy MP, Howell SB: Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol, 1987; 19(2): 149-54
21. Kishi K, Doki H, Miyata H et al: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg, 2002; 89: 597-603
22. Koropatnick J, Pearson J: Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Mol Pharmacol, 1993; 44(1): 44-50
23. Scholzen T, Gerdes J: The Ki67 protein: from the known and the unknown. J Cell Physiol, 2000; 182: 311-22
24. Weidner N, Moore DH, Vartanian R: Correlation of Ki67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using novel "paraffin"-reactive MIB-1 antibody. Hum Pathol, 1994; 25: 337-43
25. Scalzo DA, Kallakury BVS, Gaddipati RV et al: Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol, 1998; 109: 163-68
26. Huuhtanen RL, Blomquist CP, Wiklund TA et al: Comparison of the Ki67 score and S-phase fraction as prognostic variables in soft-tissue sarcomas. Br J Cancer, 1999; 79: 945-51
27. Borre M, Bentzen SM, Nerstroem B, Overgaard J: Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol, 1998; 159: 1609-14
28. Miguel-Garcia A, Matutes E, Tann F et al: Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy. J Clin Pathol, 1995; 48: 935-39
29. Zasławski R, Surowiak P, Dziȩgiel P et al: Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle. Med Sci Monit, 2001; 7(5): 908-13
30. Midulla C, De Iorio P, Nagar C et al: Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res, 1999; 19(5B): 4033-37
31. Ploton D, Menager M, Jeannesson P et al: Improvement in the staining and in the visualisation of the agyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J, 1986; 18: 5-14
32. Leong AS-Y, Gilham P: Silver staining of nucleolar organizer regions (NORs) in malignant melanoma and melanotic nevi. Hum Pathol, 1989; 20: 257-62
33. Derenzini M, Ploton D: Interphase nucleolar organizer regions in cancer cells. Int Rev Exp Pathol, 1991; 32: 150-64
34. Schwint A, Gomez M, Itoz M, Cabrini R: Nucleolar organizer regions as a markers of incipient cellular alterations in squamous epithelium. J Dent Res, 1993; 72: 1233-36
35. Remmele W, Stenger HE: Recomendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 1987; 8(3): 138-40
36. Clahsen PC, Van de Velde CJH, Duval C et al: The utility of mitotic index, oestrogen receptor and Ki67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Sur Oncology, 1999; 25: 356-63
37. Railo M, Nordling S, Von Boguslawski K et al: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer, 1993; 68: 579-83
38. Warnberg F, Nordgren H, Bergkvist L, Holmberg L: Tumour markers in breast carcinoma correlate with grade rather with invasiveness. Br J Cancer, 2001; 85(6): 869-74
39. Giri DD, Nottingham JF, Lawry J et al: Silver-binding nucleolar organizer regions (AgNORs) in benign and malignant breast lesions: correlation with ploidy and growth phase by DNA flow cytometry. J Pathol, 1989; 157: 307-13
40. Izarusta SP, Vassalo J, Magna LA et al: The value of PCNA and AgNOR staining in endoscopic biopsies of gastric mucosa. Pathol Res Pract, 1998; 194(1): 33-39
41. Galland P, Dagraef C: Cyclin/PCNA immunostaining as an alternative to tritiated thymidyne pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet, 1989; 22: 383-92
42. Surowiak P, Dziȩgiel P, Matkowski R et al: Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7 year-course of the disease. Fol Histochem Cytobiol, 2002; 40(2): 105-6
43. Jin R, Chow VT, Tan PH et al: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogensis, 2002; 23(1): 81-86
44. Van den Oord JJ, De Ley M: Distribution of metallothionein in normal and pathological human skin. Arch Dermat Res, 1994; 286(1): 62-68